Iovance Biotherapeutics develops cell therapies based on tumor-infiltrating lymphocytes (TILs) for solid tumors. Its flagship product Amtagvi (lifileucel) is an autologous TIL therapy approved for advanced melanoma after prior treatment. The company manufactures personalized cell products and aims to expand TIL approaches into additional cancer indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 49.3 | — | -116.2 | — |
| Q2 2025 | 60 | — | -111.7 | — |
| Q3 2025 | 67.5 | — | -91.3 | — |
| Q4 2025 | 86.8 | — | -71.9 | — |
| Q1 2026 | 71.4 | 44.8% | -79 | — |
| Q2 2026 | 99.3 | 65.7% | -47.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Plexus Corp. (PLXS), Mobileye Global Inc. (MBLY), Grupo Financiero Galicia S.A. (GGAL), Figure Technology Solutions, Inc. (FIGR), Sprouts Farmers Market, Inc. (SFM), AAON, Inc. (AAON)